Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
CD19-CD34t metabolically programmed CAR transduced T-cells(Medical University of South Carolina) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
CD19-CD34t metabolically programmed CAR transduced T-cells(Medical University of South Carolina): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers
9 min read
Peripheral arterial disease cell therapy (MultiGene Vascular Systems) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
Peripheral arterial disease cell therapy (MultiGene Vascular Systems): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP,
9 min read
CD19 CAR-T Cells(Hebei Taihe Chunyu Biotechnology) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
CD19 CAR-T Cells(Hebei Taihe Chunyu Biotechnology): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, ma
9 min read
ON-01 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
ON-01: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
ABL-104 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
ABL-104: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Ad26 Mos4 HIV tetravalent vaccine (Janssen Vaccines and Prevention B.V) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
Ad26 Mos4 HIV tetravalent vaccine (Janssen Vaccines and Prevention B.V): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP
![[177Lu]Lu-XT381 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go](https://synapse-static.patsnap.com/strapi-static/Blog_cover_02_0815c5db75.jpg)
9 min read
[177Lu]Lu-XT381 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
[177Lu]Lu-XT381: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Corneal Stromal Stem Cells(Zhongshan Ophthalmic Center) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
Corneal Stromal Stem Cells(Zhongshan Ophthalmic Center): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deal
9 min read
TGRX-814 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
TGRX-814: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Pan-T booster co-expressing MSLN CAR T cell(UTC Therapeutics) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
Pan-T booster co-expressing MSLN CAR T cell(UTC Therapeutics): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensin
9 min read
CID-103 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
CID-103: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
RS1 AAV Vector(VegaVect) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
RS1 AAV Vector(VegaVect): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key ris